Showing results (91-100 of 98) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.Resuscitation|June 1, 1997
Open-chest cardiac massage without major thoracotomy: metabolic indicators of coronary and cerebral perfusionR F Buckman, M M Badellino, C A Eynon, et al.Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 28, 2007
Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional reportC J Lee, J Scheiman, M A Anderson, et al.Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.Pageof 10